Evidence map›Paper›PMID 39722646›Full record

ArticlePharmacology research & perspectives2025

Intravitreal Administration of Avacincaptad Pegol in a Nonhuman Primate Model of Dry Age-Related Macular Degeneration.

Rintaro Fujii, Mayumi Matsushita, Yoshitaka Itani, Aldric Hama, Takahiro Natsume, Hiroyuki Takamatsu

Abstract read
In one paragraph

Article in Pharmacology research & perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rintaro FujiiHamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.
Mayumi MatsushitaHamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.
Yoshitaka ItaniHamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.
Aldric HamaHamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.ORCID 0000-0001-7372-979X
Takahiro NatsumeHamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.
Hiroyuki TakamatsuHamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.

Funding

Hamamatsu Pharma Research
6 · The paper itself

Abstract

The lack of effective treatments for dry age-related macular degeneration (AMD) is in part due to a lack of a preclinical animal model that recapitulates features of the clinical state including macular retinal pigment epithelium (RPE) degeneration, also known as geographic atrophy (GA). A nonhuman primate model of GA was developed and its responsiveness to an approved treatment, avacincaptad pegol (ACP), a complement C5 inhibitor, was evaluated. Intravitreal (ivt) administration of sodium iodate (SI) into one eye of male Macaca fascicularis leads to retinal areas (mm

Indexed as

Disease Models, AnimalGeographic AtrophyIntravitreal InjectionsMacaca fascicularisTomography, Optical CoherenceAnimalsIodatesMacular DegenerationMaleRetinaRetinal Pigment EpitheliumIodatessodium iodateage‐related macular degenerationavacincaptad pegolcolor fundus photographycynomolgus macaquefundus autofluorescencegeographic atrophy

Identifiers

PMID39722646
PMCPMC11669843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.